3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Lung Neoplasms
4
Ovarian Neoplasms
2
Neoplasms
2
Urinary Bladder Neoplasms
1
Tuberculosis, Pulmonary
1
Thoracic Diseases
1
Sedation
1
Recurrence
1
Neoplastic Cells, Circulating
1
Neoplasm Metastasis
1
Liver Neoplasms
1
Intraoral Tumor
1
Hypoxia
1
Esophageal Neoplasms
1
Emergence Delirium
1
Disease Progression
1
Delirium
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Carcinoma
1
Breast Neoplasms
1
Brain Neoplasms
1
Interventions
Cyclophosphamide
21
venetoclax
18
pembrolizumab
16
Dexamethasone
16
fludarabine
14
Cytarabine
13
Gemcitabine
9
pomalidomide
8
Rituximab
8
Carboplatin
8
Azacitidine
8
glofitamab
7
fludarabine phosphate
7
Lenalidomide
7
Immunotherapy, Adoptive
7
selinexor
6
Paclitaxel
6
Injections
6
Granulocyte Colony-Stimulating Factor
6
Cisplatin
6
daratumumab
5
Temozolomide
5
Oxaliplatin
5
Bevacizumab
5
zanubrutinib
4
ruxolitinib
4
Surgical Procedures, Operative
4
Nivolumab
4
Drug Therapy
4
Decitabine
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Recurrence
×
Propofol
×
Clear all
NCT06330038
2026-04-20
GASTIVA
Samsung Medical Center
Phase 4
Recruiting
5,384 enrolled